| Autor: |
Blind, Eberhard, Graeff, Pieter A de, Meurs, Illiana, Holtkamp, Frank, Baczynska, Ania, Janssen, Heidi |
| Předmět: |
|
| Zdroj: |
European Heart Journal; 5/7/2021, Vol. 42 Issue 18, pe2-e3, 2p |
| Abstrakt: |
The article informs that the European Medicines Agency has approved the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. It mentions that alirocumab and evolocumab are human monoclonal antibodies, that bind selectively to PCSK9, a protein that regulates the recycling of LDL receptors on the surface of liver cells. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
